CHPA Benzocaine Study Protocol Includes Consumer Research Survey
This article was originally published in The Tan Sheet
Executive Summary
Studying OTC toothache relief ingredient benzocaine in an actual use setting presents "insurmountable hurdles," the Consumer Healthcare Products Association tells FDA in an April 16 briefing document
You may also be interested in...
Benzocaine Repeat-Dosing, Three-Arm Trials Recommended By FDA’s Ganley
A three-arm benzocaine study is necessary to determine whether the existing 20% and 10% strengths are equally effective for toothache pain relief, according to FDA Division of OTC Drug Products Director Charles Ganley, MD
Benzocaine Repeat-Dosing, Three-Arm Trials Recommended By FDA’s Ganley
A three-arm benzocaine study is necessary to determine whether the existing 20% and 10% strengths are equally effective for toothache pain relief, according to FDA Division of OTC Drug Products Director Charles Ganley, MD
Benzocaine Repeat-Dosing, Three-Arm Trials Recommended By FDA’s Ganley
A three-arm benzocaine study is necessary to determine whether the existing 20% and 10% strengths are equally effective for toothache pain relief, according to FDA Division of OTC Drug Products Director Charles Ganley, MD